Bao B, Mitrea C, Wijesinghe P, et al. (2017). Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep., 7: 44125.
Mitrea C, Wijesinghe P, Dyson G, Kruger A, Ruden
D, Draghici S, Bollig-Fischer A. (2017). Integrating 5hmC and gene expression data to infer regulatory mechanisms. Bioinformatics, .
Adv Exp Med Biol,
Wijesinghe, P., & Bollig-Fischer, A. (2016). Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. . Adv Exp Med Biol,, 890: 1-23.
Journal of Thoracic Oncology
Wijesinghe, P., Bepler, G., and Bollig-Fischer, A. (2015). A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Gene Fusions in Non-small Cell Lung Cancer, . Journal of Thoracic Oncology, 10: 381-386.
Bollig-Fischer, A., Michelhaugh, S. K., Wijesinghe, P., et al. (2015). Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget, 6(16): 14614-14624.
Nucleic Acids Res
Wijesinghe, P. and Bhagwat, A.S. (2012). Efficient Deamination of 5-Methylcytosines in DNA by Human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res, 40: 9206-9217.
DNA Repair (Amst)
Carpenter, M.A., Rajagurubandara, E., Wijesinghe, P. and Bhagwat, A.S. (2010). Determinats of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amst), 9: 579-587.